scLR

scLR identifies and analyzes dysregulated ligand-receptor interactions between conditions using single-cell transcriptomic data to characterize changes in cell-cell communication.


Key Features:

  • Simultaneous consideration of ligands and receptors: Considers ligand and receptor expression jointly to identify dysregulated interactions across multiple conditions.
  • Statistical modeling of expression product: Models the distribution of the product of ligand and receptor expression values to assess interaction changes.
  • Accounting for inter-sample variance and small sample sizes: The modeling approach explicitly accounts for inter-sample variances and limited sample sizes common in single-cell studies.
  • Validation by simulation studies: Simulation studies demonstrate high sensitivity and specificity for detecting significant changes in interactions.

Scientific Applications:

  • Study of cellular communication in biological processes: Applicable to investigations of differentiation, development, homeostasis, and inflammation.
  • Cytokine signaling in COVID-19: Used to uncover cytokine signaling between macrophages and proliferating T cells during severe acute COVID-19 infection.
  • TGF-β signaling in pulmonary fibrosis: Identified activated TGF-β signaling from alveolar type II cells in the pathogenesis of pulmonary fibrosis.

Methodology:

Models the distribution of the product of ligand and receptor expressions and incorporates inter-sample variance and small sample size considerations to detect dysregulated interactions across conditions.

Topics

Details

License:
Not licensed
Cost:
Free of charge
Tool Type:
library
Operating Systems:
Mac, Linux, Windows
Programming Languages:
R
Added:
7/25/2022
Last Updated:
11/24/2024

Operations

Publications

Liu Q, Hsu C, Li J, Shyr Y. Dysregulated ligand–receptor interactions from single-cell transcriptomics. Bioinformatics. 2022;38(12):3216-3221. doi:10.1093/bioinformatics/btac294. PMID:35482476. PMCID:PMC9191214.

PMID: 35482476
PMCID: PMC9191214
Funding: - National Cancer Institute: U2C CA233291, U54 CA217450 - National Institutes of Health: P01 AI139449 - Cancer Center Support Grant: P30CA068485